VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Actinobacillus pleuropneumoniae ureC and apxIIA double mutant deletion vaccine
Vaccine Information
  • Vaccine Name: Actinobacillus pleuropneumoniae ureC and apxIIA double mutant deletion vaccine
  • Target Pathogen: Actinobacillus pleuropneumoniae
  • Target Disease: porcine pleuropneumonia
  • Type: Live, attenuated vaccine
  • Status: Research
  • apxIIA gene engineering:
    • Type: Gene mutation
    • Description:
    • Detailed Gene Information: Click Here.
  • ureC gene engineering:
    • Type: Gene mutation
    • Description:
    • Detailed Gene Information: Click Here.
  • Preparation: To construct the A. pleuropneumoniae serotype 2 isogenic mutant, 12 clinical isolates were tested initially with respect to their amenability to genetic manipulation via conjugation and cointegration of pBMKUΔ1 (Tonpitak et al., 2002).
  • Immunization Route: aerosol immunization
Host Response

Pig Response

  • Persistence: In all pigs, an immune response could be detected in the detergent extract enzyme-linked immunosorbent assay (ELISA), and only in the wild-type group six of seven pigs showed elevated levels (>10 ELISA units [EU]) in the ApxIIA ELISA 3 weeks after challenge. These results showed that the A. pleuropneumoniae double-mutant strain is highly attenuated and that the group infected with the mutant strain can be discriminated from the wild-type-infected group based on the ApxIIA ELISA (Tonpitak et al., 2002).
  • Efficacy: A single aerosol application of the attenuated double mutant resulted in protection from clinical disease comparable to that obtained with two applications by using a conventional bacterin vaccine. In addition, immunized pigs were protected significantly from colonization of the lungs (Tonpitak et al., 2002).
References
Tonpitak et al., 2002: Tonpitak W, Baltes N, Hennig-Pauka I, Gerlach GF. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine. Infection and immunity. 2002; 70(12); 7120-7125. [PubMed: 12438394].